Ouvrages publiés en collaboration (1)
  1. 1. Taton, O., Bondue, B., & Roufosse, F. (2022). Hypereosinophilic syndromes and lung involvement.
    2.   Parties d'ouvrages collectifs (9)
  2. 1. Gelfand, E. E., Simon, D., Simon, H.-U., Thomas, P. A., Busse, W. W., Nair, P., Gauvreau, G. G., Denburg, J. J., Bivins-Smith, E. E., Jacoby, D., Davis, B. B., Rothenberg, M., Khoury, P., Klion, A., Lotfi, R., Spada, N., Lotze, M. T., Schleimer, R. R., Kato, A., Kern, R., Lavigne, M. M., Eppihimer, M. M., Roufosse, F., Le Moine, A., Massart, A., Benghiat, F., Lemaitre, P., Krahn, M., Bartoli, M., & Levy, N. (2013). Eosinophils in Human Disease. In Eosinophils in Health and Disease (pp. 431-536). Elsevier Inc. doi:10.1016/B978-0-12-394385-9.00013-4
  3. 2. Roufosse, F., Massart, A., Benghiat, F., Lemaitre, P., & Le Moine, A. (2012). Eosinophils and Allograft Rejection. In J. L. Lee & H. F. Rosenberg (Eds.), Eosinophils in Health and Disease. Academic Press, Elsevier.
  4. 3. Roufosse, F., Goldman, M., Cogan, E., & Lottenberg, R. (2009). Hypereosinophilia: Primary and Secondary. In Evidence-Based Hematology (pp. 221-228). John Wiley and Sons. doi:10.1002/9781444300857.ch27
  5. 4. Roufosse, F., Klion, A. D., & Weller, P. F. (2009). Treatment of the hypereosinophilic syndromes. In UpToDate. Waltham, MA: UpToDate, Basow, DS.
  6. 5. Roufosse, F., Klion, A. D., & Weller, P. F. (2009). Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes. In UpToDate. Waltham, MA: UpToDate, Basow, DS.
  7. 6. Roufosse, F., Goldman, M., & Cogan, E. (2009). Hypereosinophilic syndromes. In Urticaria and Angioedema. Informa Healthcare publishers.
  8. 7. Roufosse, F., Goldman, M., & Cogan, E. (2008). Hyperesoinophilia: primary and secondary. In Evidence Based Hematology. Blackwell Publishers.
  9. 8. Roufosse, F., Goldman, M., & Cogan, E. (2004). Idiopathic hypereosinophilic syndrome. In Orphanet Encyclopedia (pp. 1-7).
  10. 9. Goldman, M., Bartholomé, E. J., & Roufosse, F. (2000). Mechanisms of action and clinical uses of type-I interferons. In A. Mantovani & P. Ghezzi (Eds.), Pharmacology of Cytokines (pp. 279-318). Oxford University press.
    11.   Articles dans des revues avec comité de lecture (70)
  11. 1. Chen, M., Roufosse, F., Wang, S. S., Verstovsek, S., Durrani, S. S., Rothenberg, M., Pongdee, T., Butterfield, J. H., Lax, T., Wechsler, M. M., Stein, M. L., Ogbogu, P. U., Kahwash, B. B., Mathur, S. S., Simon, D., Akuthota, P., Holland, N., Wetzler, L., Ware, J. A. J., Guo, C., Fay, M. M., Khoury, P., Klion, A., & Bochner, B. (2022). An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes. Journal of Allergy and Clinical Immunology: In Practice. doi:10.1016/j.jaip.2022.02.006
  12. 2. Jackson, D. J., Akuthota, P., & Roufosse, F. (2022). Eosinophils and eosinophilic immune dysfunction in health and disease. European respiratory review : an official journal of the European Respiratory Society, 31(163). doi:10.1183/16000617.0150-2021
    13. << Précédent 1 2 3 4 5 6 7 8 Suivant >>